PR88165

BEIJING and BRIDGEWATER, N.J., Feb. 22, 2021 /PRNewswire=KYODO JBN/ --

    Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee)

(SANGHAI: 603087.SH), a global biopharmaceutical company, has announced a

collaborative partnership with the International Diabetes Federation (IDF) that

aims to support their global efforts of promoting diabetes care and prevention

worldwide. This collaboration will allow opportunities to support future

initiatives such as medical education through the IDF School of Diabetes as

well as becoming inaugural partners in the launch of the IDF WeChat platform in

China. This partnership will also provide the opportunity to participate in

advocacy initiatives such as World Diabetes Day and the Centenary of Insulin.

“Gan & Lee’s collaboration with IDF will provide an opportunity to support

global outreach and advocacy initiatives to help improve the lives of people

affected by diabetes”, said Kai Du, CEO of Gan & Lee Pharmaceuticals, Chairman

of Gan & Lee USA Corporation.

    Diabetes care is multidimensional due to complex interactions between

environmental, lifestyle, clinical, and genetic factors. These unique

complications, along with access to continuing care, education, and medication,

strongly influence the clinical course.  According to the latest edition of the

IDF Diabetes Atlas, approximately 463 million adults (20-79 years) were living

with diabetes in 2019 and this number is expected to rise to 700 million by

2045. Additionally, 1 in 2 people with diabetes in 2019 were undiagnosed1. Gan

& Lee understands the importance of supporting online educational resources and

advocacy initiatives for people affected by diabetes. “The International

Diabetes Federation is delighted to welcome Gan & Lee as a partner to support

our global awareness, advocacy and education initiatives. In a year that marks

the centenary of the discovery of insulin, coordinated and collaborative action

to ensure affordable and uninterrupted care and education for every person

living with diabetes, regardless of where they live or their economic

circumstances, is more important than ever.” said Prof. Andrew Boulton,

President, International Diabetes Federation.

    About Gan & Lee

    Gan & Lee successfully developed the first Chinese domestic biosynthetic

human insulin. The company has five recombinant insulin analogs commercialized

in China including long-acting glargine injection (Basalin®), fast-acting

lispro injection (Prandilin®), fast-acting aspart injection (Rapilin™), mixed

protamine zinc lispro injection (25R) (Prandilin®25), aspart 30 injection

(Rapilin™30), reusable insulin injection pen (GanleePen™) and disposable pen

needle (Ganlee Fine™). Contact us at investorrelations@ganlee.us.

    References

    1. International Diabetes Federation. IDF Diabetes Atlas, 9th ed. 2019.  

https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf

    Media Contact: Gina Antonucci, 888-288-5395, investorrelations@ganlee.us

Source: Gan & Lee Pharmaceuticals Co., Ltd.